PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026Small6 citations

Vertically Stacked Paper‐Based Microarray Device for High‐Throughput SERS Detection of Two Cancer Biomarkers

View Full Paper
JQJi QiChinese Academy of SciencesJCJiadong ChenChung-Ang UniversityQYQian YuChung-Ang University

Key Points

  • The research aims to develop a cost-effective microarray device that enables efficient detection of cancer biomarkers using SERS technology.
  • Developed a vertically stacked microarray paper-based device (µAPAD) comprising 16 layers.
  • Integrated microfluidic channels for optimized sample flow and nanotag distribution.
  • Conducted multiplex immunoassays for carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP).
  • Evaluated analytical performance with spiked serum samples.
  • Achieved detection limits of 0.34 ng/mL for CEA and 0.69 ng/mL for AFP.
  • Reduced signal variation from 36.6% to 6.69% through improved nanotag distribution.
  • Demonstrated reliable recoveries of 80.3%–139% in serum testing with RSDs of 6.30%–10.8%.
  • Enabled simultaneous analysis of 14 samples within 30 minutes.

Abstract

ABSTRACT The demand for point‐of‐care (POC) diagnostics is driving portable analytical innovation. Despite advances, precise optical tag control remains a key challenge limiting diagnostic accuracy. Here, we present a vertically stacked microarray paper‐based device (µAPAD) enabling high‐throughput surface‐enhanced Raman scattering (SERS) immunoassays for multiplex biomarker detection. The 16‐layer wax‐patterned architecture integrates sample migration, reaction, and capture within one platform. Optimized microfluidic channels ensure uniform nanotag distribution, reducing signal variation from 36.6% to 6.69%, while an agarose hydrogel layer regulates flow to improve immunocapture efficiency. The µAPAD simultaneously analyzes 14 samples for two biomarkers within 30 min. Using carcinoembryonic antigen (CEA) and alpha‐fetoprotein (AFP) as models, it achieves detection limits of 0.34 and 0.69 ng/mL, outperforming conventional ELISA. Tests with spiked serum confirm high analytical accuracy, showing recoveries of 80.3%–139% and RSDs of 6.30%–10.8%. With its high sensitivity, flow precision, scalability, and true multiplexing capability, this low‐cost platform offers great potential for next‐generation POC diagnostics and large‐scale health monitoring.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Qi et al. (2026) studied this question.

synapsesocial.com/papers/69cd7a815652765b073a7b47https://doi.org/10.1002/smll.202514850
Ask AI
Helpful
Bookmark
Share
View Full Paper